Department of Neurosurgery, Zhongshan Hospital Xiamen Unviersity, Xiamen, China.
Department of Medical Affairs, Techpool Bio-pharma Co., Ltd., Shanghai, China.
Brain Behav. 2018 Oct;8(10):e01060. doi: 10.1002/brb3.1060. Epub 2018 Aug 29.
To evaluate the clinical efficacy of Human Urinary Kallidinogenase (HUK) on the outcome of patients with ruptured intracranial aneurysm.
This was a prospective, open-label study. At the Department of Neurosurgery in our hospital, 127 patients were treated and operated due to ruptured intracranial aneurysm in the period 2015-2016. After surgery, all the patients received basic treatment and 70 patients received additional HUK treatment (HUK group) according to their willing. In detail, 0.15 PNA unit of HUK injection plus 100 ml saline in intravenous infusion was performed, with once a day for 14 consecutive days. The modified Rankin Scale (mRS) scores and favorable mRS rates (mRS 0-1) were analyzed 3-month after the treatment.
No difference was shown in the basic characteristics between the two groups (p > 0.05). Favorable mRS rate in the HUK group (71.43%) was significantly higher than that in control group (50.88%, p < 0.05). In addition, 3-month death rate was significantly lower in the HUK group. Delayed ischemic stroke rate was similar between the two groups.
HUK can reduce morbidity and mortality of patients with ruptured intracranial aneurysm after surgery.
评估人尿激肽原酶（HUK）治疗破裂颅内动脉瘤患者的临床疗效。
这是一项前瞻性、开放标签的研究。在我院神经外科，2015 年至 2016 年期间，127 名患者因颅内破裂动脉瘤接受了治疗和手术。手术后，所有患者均接受了基础治疗，70 名患者根据意愿接受了额外的 HUK 治疗（HUK 组）。具体而言，静脉输注 0.15 PNA 单位的 HUK 注射液加 100ml 生理盐水，每天一次，连续 14 天。治疗 3 个月后，分析改良 Rankin 量表（mRS）评分和良好 mRS 评分率（mRS 0-1）。
两组基本特征无差异（p>0.05）。HUK 组的良好 mRS 评分率（71.43%）明显高于对照组（50.88%，p<0.05）。此外，HUK 组 3 个月死亡率明显较低。两组迟发性缺血性卒中发生率相似。
HUK 可降低破裂颅内动脉瘤患者手术后的发病率和死亡率。
